The aim of the study was to quantitatively predict the clearance of three antibiotics, amikacin, vancomycin, and teicoplanin, during continuous hemodiafiltration (CHDF) and to propose their optimal dosage in patients receiving CHDF. For this goal, in vitro CHDF experiments with a polyacrylonitrile (PAN) membrane were first performed using these antibiotics, and then the clearances were compared with in vivo CHDF situations determined in 16 critically ill patients. The in vitro CHDF clearances were described as the product of the outflow rate of a drain (Q outflow ) and the drug unbound fraction in artificial plasma, indicating that drug adsorption to the PAN membrane has minor effect on drug clearance in our settings. The observed in vivo clearances also agreed very well with the predicted values, with a product of Q outflow and plasma unbound fraction, when residual creatinine clearance (CL CR ) was taken into account (within a range of 0.67-to 1.5-fold for 15 of 16 patients). Based on these results, a nomogram of the optimized dosages of amikacin, vancomycin, and teicoplanin was proposed, and it was evident that Q outflow and residual CL CR are major determinants of the dosage and dosing interval for these antibiotics. Although the applicability needs to be confirmed with another type of membrane or higher Q outflow , our nomogram can help determine the dosage setting in critically ill patients receiving CHDF.
Continuous renal replacement therapy (CRRT), such as continuous hemofiltration (CHF), continuous hemodialysis (CHD), and continuous hemodiafiltration (CHDF), is frequently used as an adjunctive therapy to treat critically ill patients with multiple organ failure or other severe diseases. However, it is well-known that as well as removing uremic compounds, CRRT also clears some therapeutic agents from the body and alters their pharmacokinetics and may therefore result in inadequate therapeutic responses (10, 31, 38) . This is particularly problematic in critically ill patients suffering from life-threatening infections such as sepsis and pneumonia because the risk of underdosage of antibiotics during CRRT can lead not only to therapeutic failure but also to the spread of drug-resistant strains (10) . Furthermore, it is difficult for physicians to titrate the dosage of antibiotics in accordance with changes in the clinical biomarkers because the progression of severe infection is drastic. Therefore, it is important to predict alterations in the pharmacokinetic properties of antibiotics during CRRT and to set up individualized dosing regimens (10, 32) .
There are a number of reports concerning drug removal by the three major CRRT modes (i.e., CHD, CHF, and CHDF), with drug removal by CHF being the most extensively studied. Drug clearance by CHF is described as a product, S C ϫ Q F , where S C is the sieving coefficient and Q F is the ultrafiltration rate (31) . S C is calculated by dividing the drug concentration in the ultrafiltrate by that in the plasma (18) . Drug removal during CHD has been studied for several antibiotics (2, 22, 46, 48, 49) , and the clearance is described as a product, S d ϫ Q D , where S d is the saturation coefficient calculated by dividing the drug concentration in the dialysate by that in the plasma and Q D is the flow rate of the dialysate. Both S C and S d depend on the plasma unbound fraction (f P ) (31) .
For CHDF, during which a broad range of molecules are efficiently removed by coupling the dialysis and convection clearances, pharmacokinetic alterations of various antibiotics have been studied (10) . Several methods have been applied for the description of CHDF clearance (CL CHDF ); the simplest method, which describes CL CHDF as a product, S d ϫ Q outflow , where Q outflow represents the sum of Q D and Q F (21) , is frequently applied. This method seems suitable for the prediction of pharmacokinetic properties of drugs if the S d values during CHDF are determined based on f P , as in the cases of CHF and CHD. However, in past studies, some discrepancies between S C (or S d ) and published f P values of drugs have been observed (8) . It has been speculated that the underlying mechanism for this discrepancy is based on the change in protein binding in patients with severe renal failure (8, 10) , but this hypothesis has not been investigated and remains to be confirmed.
The aims of the present study were to quantitatively predict the clearance of three antibiotics during CHDF and to propose their optimal dosage in patients receiving CHDF, with particular focus on the individual f P values, Q outflow , and the desirable pharmacokinetic/pharmacodynamic (PK/PD) index of each antibiotic. For this purpose, we selected three antibiotics, vancomycin (VAN), amikacin (AMK), and teicoplanin (TEC), with various f P values and PK/PD characteristics (31, 32, 36, 46) . AMK has a high f P , and its efficacy is strongly related to peak concentration (C peak )/MIC. In contrast, VAN has a moderate f P , and the area under the concentration-time curve over 24 h (AUC 0-24 h )/MIC is the most important PK/PD index for determining efficacy. The antibacterial effect of TEC also depends on the AUC 0-24 h /MIC but it has a low f P . We conducted an in vitro study of the clearance of these drugs during CHDF. We then analyzed the therapeutic drug monitoring (TDM) data from patients who were admitted to the intensive care unit (ICU) and received intravenous administration of one of these three antibiotics during CHDF, with special attention to the setting of Q F and Q D . On the basis of the pharmacokinetic analysis described in this paper, nomograms for the optimal dosage strategy of VAN, TEC, and AMK during CHDF were constructed with special consideration given to the PK/PD relationships (12, 32, 37) .
MATERIALS AND METHODS

In vitro study. (i)
In vitro CHDF system. Figure 1 depicts the configuration of the in vitro CHDF system (20) , which is composed of a hemodiafiltration apparatus (ACH-10; Asahi Medical Co., Tokyo, Japan) and a high performance polyacrylonitrile (PAN) membrane (PANFLO-APF-10S; effective filtration area, 1.0 m 2 ; Asahi Medical Co.). A standard bicarbonate solution (Sublood B; Fuso Pharmaceutical Co., Osaka, Japan) was used for the dialysate and the substitution solution (Fig. 1) . Artificial plasma was prepared by dissolving human serum albumin (HSA) in normal saline at a concentration of 5% (wt/vol) (20) and was spiked with AMK, VAN, or TEC to give a final concentration of 50 mg/liter. A solution of HSA was used because the f P of these drugs is reported to be inversely correlated with the plasma albumin concentration (1, 13, 35) , which suggests that albumin is the major binding protein for these drugs. Spiked artificial plasma was added to a 2-liter Erlenmeyer flask and kept at 37°C with continuous mixing by a magnetic stirrer. The in vitro CHDF system was primed with approximately 200 ml of 5% HSA prior to the initiation of the experiment.
The CHDF conditions were as follows: the duration of CHDF was 360 min, the artificial plasma flow rate (Q B,in ) was 80 ml/min, the dialysate flow rate (Q D ) was 6.67 ml/min (400 ml/h), the ultrafiltration rate (Q F ) was set at 6.67 ml/min (400 ml/h) by controlling the hydrostatic pressure, and the substitution flow rate (Q S ) was 6.67 ml/min (400 ml/h). Inflow and outflow artificial plasma specimens (0.5 ml) were collected at 30, 60, 90, 120, 180, 240, and 360 min after initiation of CHDF. The drain from the CHDF apparatus (0.5 ml) was also collected at the same time points (Fig. 1) . All specimens were stored at Ϫ20°C until assay.
Concentrations of AMK and VAN in the artificial plasma were measured using a fluorescence polarization immunoassay (FPIA) kit (TDx system; Abbott, Abbott Park, IL) according to the manufacturer's protocol. Concentrations of TEC were determined with an FPIA kit obtained from Seradyn Inc. (Indianapolis, IN). The low limits of quantification were 2 mg/liter for AMK and VAN and 4 mg/liter for TEC, which were sufficient to determine the drug concentration of specimens obtained in this study.
(ii) Determination of protein binding of AMK, VAN, and TEC in 5% HSA. In our prediction model described later in this paper, CL CHDF strongly depends on the f P of the drugs, which is affected by the individual serum albumin concentration (ALB). Therefore, it is necessary to estimate the f P of these antibiotics as a function of ALB in each patient using the Scatchard equation (47) . The Scatchard equation is widely applied to quantitatively analyze the relationships between protein concentration and the f P of drugs (see Appendix for details). For this purpose, the unbound fractions of AMK, VAN, and TEC in 5% HSA (f U,HSA ) were determined experimentally by an ultrafiltration method described elsewhere (6) . The details of the procedure are described in the Appendix.
(iii) Pharmacokinetic analysis of the in vitro CHDF system. The time profiles of drug concentration in outflow specimens (C P,out ) were analyzed with the one-compartment model, and the in vitro clearance of AMK, VAN, and TEC during in vitro CHDF (CL CHDF,vitro ) was calculated by the following equation:
where AUC is the area under the concentration-time curve. The dose in this study was 50 mg. The saturation coefficient (S d ) was calculated at each time point by the following equation:
where C drain and C P,in represent the drug concentrations in drain and outflow specimens, respectively. In addition, to evaluate the adsorption of drugs to the dialyzer membrane, the total amount of antibiotics recovered from the drain (X d ) was calculated by the following equation:
where Q outflow is the flow rate of the drain and is equal to the sum of Q D and Q F . AUC drain is the area under the concentration-time curve of the drain and was calculated with extrapolation to infinity assuming that the time profiles of C drain were described by a one-compartment model. selected: (i) CHDF with a PAN membrane had been conducted for at least 2 consecutive days, (ii) AMK, VAN, or TEC was administered intravenously, (iii) at least one point of the trough concentration (C trough ) was determined during CHDF, and (iv) detailed information on the CHDF settings was available from clinical records. As a result of the survey of the clinical records of the patients admitted to the ICU, 3, 2, and 11 subjects had satisfied the aforementioned criteria and had been administered AMK, TEC, and VAN, respectively. Characteristics and CHDF conditions of the study subjects are summarized in Table 1 . To obtain vascular access, a polyvinyl catheter was inserted into a jugular or femoral vein. Dialysate and substitution solution were Sublood BS (Fuso Pharmaceutical Co.), and substitution solution was supplied by a postdilutional method. The Q outflow values in this study (12 to 35 ml/h/kg of body weight in most cases) are common conditions in routine clinical settings in Japan, although a higher Q outflow is often used in the United States (9, 44) .
(ii) Determination of in vivo clearance. In vivo CHDF clearances (CL CHDF,vivo Observed ) of VAN, AMK, and TEC were determined from their plasma concentration measured at the last time point during CHDF. CL CHDF,vivo Observed was estimated by Bayesian estimation using VCM-TDMEX software version 2.0 (Shionogi, Osaka, Japan) for VAN and Tagocid TDM software version 1.1 (Astellas, Osaka, Japan) for TEC. The population pharmacokinetic parameters (i.e., distribution volume of central compartment [V c ] and rate constants for the transfer from the central compartment to the peripheral compartment and for the opposite direction [k 12 and k 21 , respectively]) of VAN and TEC are summarized in Table 2 (29, 33) . To conduct the Bayesian estimation for VAN and TEC, CL CR was calculated using the Cockcroft-Gault equation and S cr at the final time point (11) . The CL CHDF,vivo
Observed of AMK was calculated using the assumption that all other parameters (i.e., V c , k 12 , and k 21 ) were fixed. These parameters were determined based on the reported concentration-time profile of AMK in critically ill patients (40) and are summarized in Table 2 .
(iii) Prediction of in vivo clearance. The predicted CHDF clearance (CL CHDF,vivo Predicted ) of each subject was calculated using the following equation:
where f P represents the plasma unbound fraction of antibiotic in the subject and CL CR represents the residual creatinine clearance, which is calculated by dividing the amount of creatinine excreted into the urine by the AUC of serum creatinine. Because AMK, TEC, and VAN are cleared from the body primarily via glomerular filtration, f P ϫ CL CR was added to f P ϫ Q outflow to adjust the involvement of residual renal clearance if the CL CR of the subject was available and significant. When the calculated CL CR was below 5 ml/min, it was considered negligible. If the CL CR values were unavailable because of insufficient urinary creatinine concentration data, these subjects were analyzed separately from the subjects whose CL CR values were available. The f P was corrected by ALB for each patient on the basis of the Scatchard equation (see Appendix for details).
(iv) Simulation of time profiles of AMK, VAN, and TEC in patients receiving CHDF. To examine the feasibility of predicting individual pharmacokinetics using CL CHDF,vivo Predicted as described above, the concentration-time profiles of the antibiotics were simulated based on CL CHDF,vivo Predicted , dosing history, and body weight (BW) of the patients. Simulation was initiated from the time point of initial administration of antibiotics if the CHDF had been introduced prior to the initial dose. If the CHDF was introduced after the initial dose, the time point for the first concentration data of antibiotics during CHDF was defined as time zero.
A two-compartment model was applied for the simulation of VAN, AMK, and TEC. Equations for the simulation were developed according to a standard (47), and the pharmacokinetic parameters described in Table 2 (V c , k 12 , and k 21 ) were used for the simulation. Construction of nomograms of the dosage regimens of AMK, VAN, and TEC for patients receiving CHDF. Based on the pharmacokinetic analysis described above, nomograms of the dosage regimens of AMK, VAN, and TEC during CHDF were constructed to achieve the desired PK/PD index.
The optimized dosage regimen of VAN was proposed to achieve an AUC 0-24 h / MIC of 400 (36), together with a C trough of 10 to 20 mg/liter to avoid nephrotoxicity (25) and the appearance of resistant strains (36) . The MIC of the pathogen (e.g., methicillin-resistant Staphylococcus aureus [MRSA] ) was set at 1 or 2 mg/liter (19, 36) . In the same manner, the dosage regimens of TEC were calculated to achieve an AUC 0-24 h /MIC of 345 (23) . The target C trough of TEC was set at 10 to 60 mg/liter because a C trough of Ͻ10 mg/liter is considered suboptimal and a C trough of Ͼ60 mg/liter is toxic (43) . The MIC of the pathogen (e.g., MRSA) was set at 2 or 4 mg/liter (14, 26) . For AMK, the optimal dosage regimen was proposed to achieve a C peak /MIC of 8 together with a C trough of Ͻ5 mg/liter to optimize antibacterial activity and to minimize nephrotoxicity (4, 28) . The MIC of the pathogen (e.g., Pseudomonas aeruginosa) was set at 4 or 8 mg/liter (14, 26) . Dosing regimens of the three antibiotics were expressed as a function of (Q outflow ϩ CL CR )/BW.
RESULTS
In vitro CHDF clearance. The time profiles of C P,out in in vitro studies were described satisfactorily by a one-compartment model with first-order elimination for all three antibiotics used in the study, indicating that the clearance by CHDF was constant during the experiment. CL CHDF,vitro values determined by the fitting are summarized in Table 3. Table 3 also lists the S d and f U,HSA values. S d correlated significantly with f U,HSA (r 2 ϭ 0.92). In addition, there was an excellent correlation between CL CHDF,vitro and f U,HSA ϫ Q outflow (r 2 ϭ 0.92), and the values of CL CHDF,vitro for AMK, VAN, and TEC were within a range of 0.5-to 2-fold of f U,HSA ϫ Q outflow . Theoretically, under an assumption of complete equilibrium between artificial plasma and dialysate, CL CHDF,vitro can be determined by a product, f U,HSA ϫ Q outflow , which is consistent with the present observation. The recoveries of the antibiotic dose into the dialysate were almost quantitative: 122% Ϯ 3%, 108% Ϯ 7%, and 111% Ϯ 5%, for AMK, VAN, and TEC, respectively (mean Ϯ standard deviation [SD], Table 3 ).
In vivo study. Based on the plasma concentrations of antibiotics, in vivo clearance values (CL CHDF,vivo Observed ) were calculated for each subject and compared with the predicted values (CL CHDF,vivo Predicted ). As shown in Fig. 2 , the CL CHDF,vivo Predicted correlated well with CL CHDF,vivo Observed , and CL CHDF,vivo Observed results were within the 0.67-to 1.5-fold range for all subjects, with the exception of patient 9 (VAN, 2.1-fold higher). Among patients treated with VAN, the predictions for subjects whose CL CR was available (patients 1 to 5; n ϭ 5) were more consistent with the observed values than those for subjects whose CL CR were unavailable (patients 6 to 11; n ϭ 6). Figure 3 shows the individual simulations of concentrationtime profiles of VAN (A), AMK (B), and TEC (C) based on the CL CHDF,vivo
Predicted . The simulation lines agreed very well overall with the observed concentration profile. Especially for subjects whose CL CR was available, the simulations were almost faultless. In addition, 40 out of 59 observed concentrations (68%) were within the range of 0.67-to 1.5-fold the predicted concentration and 54 out of 59 (92%) were within the range of 0.5-to 20-fold (Fig. 3D) . Discrepancies between the simulated and observed concentrations were more noticeable in VAN-treated subjects whose residual CL CR values were unavailable. The reason for the discrepancy will be addressed further in the Discussion.
Construction of nomograms of the dosage regimens for AMK, VAN, and TEC in patients undergoing CHDF. Tables 4,  5 , and 6 show the calculated optimal dosage regimens for AMK, VAN, and TEC, respectively; based on CL CHDF,vivo Predicted . Since C peak /MIC is important for predicting the efficacy of AMK, and C peak is influenced strongly by BW, the proposed AMK dosage was BW dependent (10 to 20 mg/kg) for any (Q outflow ϩ 
FIG. 2. Relationship between predicted and observed CL CHDF,vivo values. CL CHDF,vivo
Observed values of VAN, AMK, and TEC were determined for 16 subjects as described in Materials and Methods and were plotted against the CL CHDF,vivo Predicted values calculated using equation 4. Each point indicates the individual datum. Dotted lines show 2-fold and 0.5-fold differences between the observed and predicted CL CHDF,vivo , while dashed lines show 1.5-fold and 0.67-fold differences. Circle, VAN; square, TEC; triangle, AMK. Open and closed symbols indicate the subjects whose CL CR values were available (patients 1 to 5 and 12 to 15; n ϭ 9) and unavailable (patients 6 to 11 and 16; n ϭ 7), respectively. The symbol with an asterisk denotes the data from subject 9. (Table 4) . For VAN therapy, practical regimens with a dosing interval of less than 24 h were achievable if the MIC of the pathogen was 1 mg/liter. However, if the MIC increased to 2 mg/liter, the dosing interval of VAN was prolonged up to 120 h to achieve a C trough of Ͻ20 mg/liter when Q outflow was equal or less than 40 ml/h/kg. In contrast, the dosing interval of TEC could be fixed at 24 h because of its broad therapeutic range of C trough (10 to 60 mg/liter) (43) .
Significance of protein binding. ALB had a significant effect on the pharmacokinetics of the antibiotics, since CL CHDF,vivo Predicted is influenced by changes in f P and f P is a function of ALB. Figure 4 shows the relationship between ALB and the calcu-
FIG. 3. Comparison of the observed and predicted drug concentrations. Based on CL CHDF,vivo
Predicted values, the time profiles for VAN (A), AMK (B), and TEC (C) were simulated as described in Materials and Methods. Residual CL CR values were available for patients 1 to 5 and 12 to 15 (n ϭ 9) and unavailable for patients 6 to 11 and 16 (n ϭ 7). Closed circles indicate the observed drug concentrations, and the solid lines indicate the simulated lines. (D) The observed drug concentrations were plotted against the predicted concentration at corresponding time points. The circles, squares, and triangles indicate concentrations of VAN, TEC, and AMK, respectively. Dotted lines show 2-fold and 0.5-fold differences between the observed and predicted concentrations, while dashed lines show 1.5-fold and 0.67-fold differences. Open and closed symbols indicate the subjects whose CL CR values were available (patients 1 to 5 and 12 to 15; n ϭ 9) and unavailable (patients 6 to 11 and 16; n ϭ 7), respectively. For the simulation, f P values of the drugs in each patient were calculated based on the Scatchard equation using the ALB in each patient.
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lated f P of the three antibiotics in the present study. The impact of ALB on f P was greater for TEC than for AMK and VAN.
The f P values of AMK, VAN, and TEC were 0.734, 0.635, and 0.210, respectively, when the ALB was 5 g/dl, and using a Scatchard plot analysis, these values were estimated to increase to 0.847, 0.777, and 0.347, respectively, when ALB was decreased to 2.5 g/dl. As a consequence, a higher dosage is predicted for the hypoalbuminemic patients (ALB ϭ 2.5 g/dl). However, dosage increases should be carefully considered in hypoalbuminemic patients, and this is further analyzed below.
DISCUSSION
In the present study, we first performed in vitro CHDF experiments to determine the removal of AMK, VAN, and TEC from circulating artificial plasma. Next, the f U,HSA of these drugs was determined experimentally ( Table 3) . The f U,HSA of TEC (0.21) was higher than that reported previously (approximately 0.1) (7). The reason for this difference is unclear, although it may be attributed to the differences in experimental conditions. The in vitro CHDF experiments revealed that the S d was closely related to f U,HSA and that CL CHDF,vitro correlated well with the product, f U,HSA ϫ Q outflow , for all drugs analyzed (Table 3) , which suggests that equilibrium between plasma and dialysate is achieved without significant adsorption of drugs to the CHDF membrane. We predicted in vivo clearances in subjects receiving CHDF by the equation f P ϫ (Q outflow ϩ CL CR ) (equation 4), with f P values corrected by use of the Scatchard equation. This is because S C (or S d ) values of drugs during CRRT are reported to depend on f P values (31) . It has also been reported that S C or S d values may need to be adjusted individually because ALB is often altered in patients suffering from severe renal failure or by other mechanisms (8, 10) .
In the present study, no evidence was found for significant adsorption of drugs to the PAN membrane either in vitro (Table 3 ) or in vivo ( Fig. 2 and 3) . It has been reported recently that AMK significantly bound to PAN membranes in in vitro experiments (42) ; the maximum adsorption of AMK to the PAN membrane was approximately 500 mg, which is close to the daily dose of AMK. This discrepancy from the present study may be due to unknown differences in the membrane and/or dialyzer used. It is believed that the drug adsorption appears to be membrane specific (10, 31) , and therefore, mem- a Dose schedules were proposed to satisfy the following conditions: AUC 0-24h /MIC Ͼ 400 and C trough of 10 to 20 mg/liter. Calculations were performed based on CL CHDF, vivo Predicted using equation 4. Loading dose should be considered to achieve the therapeutic C trough quickly. The indicated loading dose of VAN should be administered on day 1 followed by the indicated maintenance dose from day 2.
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on June 29, 2017 by guest http://aac.asm.org/ brane adsorption may need to be considered when other types of membranes are chosen for CHDF. Among 16 subjects analyzed in the in vivo studies, CL CHDF,vivo Observed in the nine subjects for whom urinary creatinine levels were available were within the range of 0.67-to 1.5-fold that of CL CHDF,vivo Predicted , confirming the value of our prediction method (equation 4). For the remaining seven subjects, whose CL CR values were unavailable, the predictions were almost satisfactory. However, there was a significant discrepancy between CL CHDF,vivo Observed and CL CHDF,vivo Predicted (2.1-fold difference; Fig. 2 , symbol with asterisk) for one subject (subject 9). This discrepancy could be due to significant remaining renal function in subject 9, and the observed and predicted CL CHDF,vivo values in this patient become compatible if CL CR is assumed to be 15 ml/min, which is a clinically relevant value (Table 1 ). The validity of our prediction method was also assessed by comparing the predicted and observed concentrations (Fig. 3D) , and it was indicated that a 0.67-to 1.5-fold range of desired concentrations of AMK, VAN, and TEC was expected to be achieved in the majority of patients using our prediction method. It should be emphasized that our method tended to overestimate the concentrations in patients whose residual CL CR was unknown. Therefore, residual CL CR should be taken into account wherever possible for the precise estimation of drug clearance during CHDF. Using information obtained from the in vitro and in vivo studies, individualized dosage regimens of AMK, VAN, and TEC in patients receiving CHDF were proposed (Tables 4 to 6 ). Based on the results of recent clinical trials investigating the optimal flow rate of CHDF (5, 34), the Q outflow /BW of CHDF should be below 45 ml/h/kg, and therefore nomograms for these three antibiotics were constructed as a function of Q outflow /BW within a range of 10 to 45 ml/h/kg. To the best of our knowledge, this is the first report that provides individualized dosage regimens of antibiotics based on BW, the flow rate of the dialysate, and the desired PK/PD index in patients receiving CHDF.
As shown in Table 4 , the fixed AMK doses of 10 (MIC ϭ 4 mg/liter) and 20 (MIC ϭ 8 mg/liter) mg/kg were calculated from the pharmacokinetic parameters to achieve the desired C peak / MIC ratio. In contrast, the dosing interval of AMK would need to be prolonged to more than 24 h to achieve a C trough of less than 5 mg/liter in most cases, and an extensive dose of CHDF should be considered where once-a-day dosing of AMK is required. Indeed, a recent report indicated that an extensive dose of CHDF (42 to 50 ml/h/kg) was needed to achieve a C trough of below 5 to 10 mg/liter when a high daily dose of AMK (25 or 50 mg/kg) was administered (24) . This observation is consistent with our nomogram. Nevertheless, the pharmacokinetics of AMK in critically ill patients is highly variable and the feasibility of the nomogram should be verified by TDM.
The optimal dosage of VAN in patients receiving CHDF is proposed in Table 5 using a criterion of AUC 0-24 h /MIC of more than 400 (36) . When targeting the MIC of the pathogen (e.g., MRSA) of 1 mg/liter and a BW of 60 kg, the dosage regimen of VAN was calculated to be 150 to 720 mg every 24 h, which is similar to the recommended dose in the Sanford Guide 2011 (500 mg every 24 to 48 h) (17) . However, if the MIC increases to 2 mg/liter, a higher dose and longer interval would be required to achieve the target AUC 0-24 h /MIC together with the C trough of 10 to 20 mg/liter. As shown in Table 5 , a high dose of VAN (1,500 to Predicted using equation 4. b A loading dose of 12 mg/kg three times at 12-h intervals should be considered in all cases to achieve the steady state immediately. c A loading dose of 6 mg/kg three times at 12-h intervals should be considered in all cases to achieve the steady state immediately.
2,000 mg per dose for a patient with BW of 60 kg) is required and a high C peak is expected under such situations. Thus, a longer infusion time may also be necessary to reduce the risk of adverse effects (e.g., red neck syndrome or ototoxicity), which may be associated with a high C peak (16, 45) . An alternative approach would be to select other anti-MRSA antibiotics (36) such as TEC or linezolid. In addition, the need for a loading dose of VAN in patients receiving CHDF should be emphasized. In patients with normal renal function, the elimination half-life (t 1/2 ) of VAN was reported to be 5.6 h (41) and there is no need for a loading dose. In contrast, the t 1/2 of VAN is prolonged in patients receiving CHDF and it takes longer to reach the steady state. Thus, the indicated initial dose of VAN should be administrated in all cases.
For TEC, the optimal dosage regimens to achieve a AUC 0-24 h /MIC of 345 together with a C trough of 10 to 60 mg/liter are proposed (Table 6 ). A loading dose of 6 or 12 mg/kg (for a MIC of 2 or 4 mg/liter, respectively) three times at an interval of 12 h is needed for all the situations. In contrast to VAN, the target AUC 0-24 h /MIC can be achieved by adjusting only the daily dose of TEC, which would be a significant advantage over VAN in clinical settings. This advantage is attributed to the broad therapeutic range of TEC (10 to 60 mg/liter) (43) . Although adverse renal events are less common with TEC than with VAN (39) , the tolerability of TEC at a C trough of 40 to 50 mg/liter, which is the predicted C trough in our nomogram for the pathogen with a MIC of 4 mg/liter (Table  6) , has not been confirmed in a large population and needs to be investigated. Therefore, renal function should be monitored carefully when our dosage nomogram is applied to daily clinical settings.
On the other hand, it should be taken into consideration that the pharmacokinetics of TEC is significantly affected by individual variation in ALB since the protein binding of TEC is notably higher than that of the other antibiotics in this study (Fig. 4) . As shown in Table 6 , a higher dosage of TEC is required in hypoalbuminemic patients to achieve the same AUC 0-24 h /MIC index calculated based on the total (i.e., bound plus unbound) TEC concentration. Pea et al. (30) observed a similar tendency in leukemia patients treated with TEC, and this observation is also in accordance with the increased TEC clearance in hypoalbuminemic patients reported by Barbot et al. (3) . It should be noted that the unbound TEC concentration, which is believed to directly relate to the efficacy of TEC (3, 27) , is expected to increase in hypoalbuminemic patients compared with healthy subjects, as shown in Table 6 . Therefore, dose increases in hypoalbuminemic patients need to be considered very carefully.
There are several differences between our nomograms and the recommended dosage regimens reported previously. Our nomograms tend to propose higher dosages for AMK, VAN, and TEC than those in other authoritative reviews and guidelines (15, 17) . For instance, the recommended dose for AMK is 7.5 mg/kg every 24 to 48 h (15), which is lower than that of our nomogram (Table  4) . For VAN, the recommended dosage regimens in the literature are variable, probably due to differences in the CHDF settings (15) ; nonetheless, these dosages are considered intermediate dosages for MICs of 1 and 2 mg/liter in our nomogram (Table 5) . Further, the recommended dosage of TEC in the Sanford Guide (6 mg/kg every 48 h) (17) is close to the dosage in our nomogram for an MIC of 2 mg/liter (Table 6 ). Based on these comparisons, it seems that our nomograms are useful in patients infected by pathogens with a high MIC (such as 8 mg/liter for AMK, 2 mg/liter for VAN, and 4 mg/liter for TEC). However, this speculation is based only on a theoretical consideration of PK/PD theory and needs to be verified in future clinical studies.
Finally, it is necessary to discuss the limitations of our study and the proposed nomograms. First, tubular secretion of drugs was not considered (or was assumed to be negligible); therefore, our method may not be directly applicable to carbapenem or other classes of antibiotics that are subjected to extensive tubular secretion. Second, a PAN membrane was used throughout our in vitro and in vivo studies, and the effects of other types of membranes, such as polyacrylonitrile or polymethyl methacrylate, on the pharmacokinetics of antibiotics remain to be elucidated. In addition, our nomograms were constructed assuming that the substitution solution was applied by a postdilutional method and should not be directly applied to cases where the predilutional mode was used. The applicability of our nomograms to these situations needs to be verified in future studies.
In conclusion, in vivo clearance of AMK, VAN, and TEC in patients undergoing CHDF and individual concentration-time profiles of these antibiotics can be predicted successfully from the Q outflow of CHDF and clinical data such as ALB, residual CL CR , and BW. The nomograms enabled us to determine the dosage regimens of antibiotics in patients undergoing CHDF on the basis of the pharmacodynamic properties of these drugs and the MICs of the pathogens. Although the extent of drug adsorption to dialyzer membranes other than PAN needs to be tested and the appropriate evaluation method of residual CL CR remains to be developed, our nomograms may be helpful in the optimization of antibiotic therapy, at least under conditions similar to those in this study.
APPENDIX
Determination of protein binding of AMK, VAN, and TEC to HSA. The protein binding of AMK, VCM, and TEC in 5% HSA was determined by an ultrafiltration method. Briefly, 5% HSA was spiked with 20 mg/liter of AMK, VCM, or TEC. The spiked specimens were ultrafiltered using a Microcon YM-30 (Millipore, Billerica, MA), and drug concentrations in the specimens and filtrates were measured using an FPIA kit. In parallel, normal saline was spiked and ultrafiltered in the same manner to determine the adsorption of drug to the ultrafiltration membrane. The unbound fraction of drug in 5% HSA (f U,HSA ) was calculated by the following equation: f U,HSA ϭ ͑C P,filtrate /C P,specimen ͒ ϫ ͑C Saline,specimen /C Saline,filtrate ͒ (A1) where C P,specimen and C Saline,specimen represent the drug concentrations in spiked 5% HSA and saline, respectively, and C P,filtrate and C Saline -,filtrate represent the drug concentrations in the filtrate of 5% HSA and saline, respectively. The adsorption rates of drugs to the ultrafiltration membrane were 38.3% Ϯ 6.0%, 1.10% Ϯ 3.0%, and 0.00% Ϯ 2.30% (mean Ϯ SD) for TEC, VCM, and AMK, respectively. Each assay was conducted in triplicate, and mean values were used in the following pharmacokinetic analysis.
It is generally accepted that f P is dependent on the concentration of binding components in serum (i.e., albumin), and the relationship is described by the Scatchard equation (equation A2):
where n is the number of binding sites, lated as the product of n and K d for AMK, VCM, and TEIC, respectively. Individual f P values were calculated using equation A2 based on the ALB determined for each patient.
